Skip to main content

Advertisement

SpringerLink
Log in

Use of Pharmacokinetic Data Below Lower Limit of Quantitation Values

  • Commentary
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Notes

  1. My conversation with a senior FDA pharmacometrician on this issue produced the following response, “From a pharmacometrics point of view one should use good scientific judgment to decide whether to include BLOQ “observations” or not. We are open to all reasonable approaches.” (personal communication)

References

  1. Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), May 2001.

  2. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. Workshop/Conference Report – Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. AAPS J. 2007;9:E30–42.

    Article  Google Scholar 

  3. Humbert H, Cabiac MD, Barradas J, Gerbeau C. Evaluation of pharmacokinetic studies: is it useful to take into account concentrations below the limit of quantification? Pharm Res. 1996;13:839–45.

    Article  PubMed  CAS  Google Scholar 

  4. Jusko WJ, Pyszczynski NA, Bushway MS, D’Ambrosio R, Mis SM. Fifteen Years of operation of a high-performance liquid chromatographic assay for prednisolone, cortisol and prednisone in plasma. J Chrom Biomed Appl. 1994;658:47–54.

    Article  CAS  Google Scholar 

  5. Parasrampuria DA, de Boer P, Desai-Krieger D, Chow AT, Jones CR. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. J Clin Pharmacol. 2003;43:406–13.

    Article  PubMed  CAS  Google Scholar 

  6. Kong A-N, Ludwig EA, Slaughter RL, DiStefano PM, DeMasi J, Middleton E, et al. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther. 1989;46:616–28.

    Article  PubMed  CAS  Google Scholar 

  7. Qu J, Qu Y, Straubinger RM. Ultra-sensitive quantification of corticosteroids in plasma samples using selective solid-phase extraction and reversed-phase capillary high-performance liquid chromatography/tandem mass spectrometry. Anal Chem. 2007;79:3786–94.

    Article  PubMed  CAS  Google Scholar 

  8. Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, editors. Applied Pharmacokinetics & Pharmacodynamics. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 9–29.

    Google Scholar 

  9. Holford N, Jelliffe R, et al. Pharm PK Discussion – BLQ Values. http://www.boomer.org/pkin/PK07/PK2007116.html.

  10. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokin Pharmacodyn. 2001;28:481–504.

    Article  CAS  Google Scholar 

  11. Duval V, Karlsson MO. Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharm Res. 2002;19:1835–40.

    Article  PubMed  CAS  Google Scholar 

  12. Ahn JE, Karlsson MO, Dunn A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35:401–21.

    Article  PubMed  Google Scholar 

  13. Byon W, Fletcher CV, Brundage RC. Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn. 2008;35:101–16.

    Article  PubMed  Google Scholar 

  14. Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect models. AAPS J. 2009;11:371–80.

    Article  PubMed  CAS  Google Scholar 

  15. Nix ABJ, Wilson DW. Assay detection limits: concept, definition, and estimation. Eur J Clin Pharmacol. 1990;39:203–6.

    Article  PubMed  CAS  Google Scholar 

  16. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Met Disp. 2003;31:510–8.

    Article  CAS  Google Scholar 

  17. Gabrielsson J, Jusko WJ, Alari L. Modeling of dose-response-time data: four examples of generating kinetic functions from response profiles. Biopharm Drug Disp. 2000;21:41–52.

    Article  CAS  Google Scholar 

Download references

Acknowledgments and Disclosures

The author appreciates the technical assistance of Ms. Nancy Pyszczynski. This work was supported by NIH Grant GM 24211.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, 14214, USA

    William J. Jusko

Authors
  1. William J. Jusko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William J. Jusko.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jusko, W.J. Use of Pharmacokinetic Data Below Lower Limit of Quantitation Values. Pharm Res 29, 2628–2631 (2012). https://doi.org/10.1007/s11095-012-0805-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-012-0805-6

Key words

Search

Navigation